***Please visit our site to find genuine analyst reports on numerous publicly traded companies
IRIS International Inc. was up over $0.95 on below average volume early trading Friday, April 18, 2008. They recently announced the following:
Friday, April 18, 2008- IRIS INTERNATIONAL, INC., a leading developer and manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that it has presented results of its NADiA PSA Assay study at the 40th American Association of Clinical Chemistry (AACC) Oak Ridge Conference - Breakthrough Technologies for Clinical Diagnostics, at The Fairmont Hotel in San Jose, Calif. The scientific poster presentation was given yesterday by Dr. Robert Klem, Vice President of Product Development, Iris Molecular Diagnostics.
The results of the retrospective study showed that the Ultrasensitive NADiA total PSA (tPSA) Assay reliably predicts prostate cancer bio chemical recurrence (BCR) after radical prostatectomy (RP). The Company's NADiA PSA Assay detected levels and increasing levels of PSA that were previously undetectable using conventional ultra sensitive assays, thus potentially enabling the detection of BCR an average 2-1/2 years earlier than with the most sensitive commercially available tPSA assays. Research scientists analyzed stored leftover serum of 85 post-prostatectomy patients who were tested with the NADiA PSA Assay. A copy of the Scientific Poster Presentation of the NADiA tPSA Assay study results can be found on the IRIS web site at www.proiris.com. (Note: As of the date of this publication, NADiA PSA is considered an investigational assay and all product claims are subject to FDA clearance).
The study was performed by the Company's Iris Molecular Diagnostics Group (IMD) in collaboration with Dr. Eleftherios P. Diamandis MD, PhD, Head of Clinical Biochemistry at the University of Toronto and Director of Pathology and Laboratory Medicine at Mt. Sinai Hospital in Toronto. Dr. Diamandis currently serves on boards of 25 scientific journals and has published more than 400 original papers. Dr. Diamandis has received numerous awards for his contributions to cancer research including most recently, Investigator of the Year Award from the American Association of Clinical Chemistry and the Morton K. Schwartz Award for Significant Contributions in Cancer Research Diagnostics. He currently serves as a consultant to Iris Molecular Diagnostics.
"Our findings could very well become the basis to monitor biochemical recurrence of PSA much earlier than conventional PSA assays," said Chairman, President and Chief Executive Officer Cesar Garca. "This study is an important milestone in our corporate history and we congratulate our IMD team and Dr. Diamandis for this significant achievement."
Our initial coverage of companies, updated daily, will include research in the following areas:
* Margin changes, specifically operating, gross, and then net
* The pace and quality of top line growth
* The ability to generate cash
* The pace and quality of the bottom line growth
* Market share gains
* Innovation/pipeline
* Corporate governance
* Management's ability to operate in unfavourable environments
* The ability of management to control acquisitive growth and achieve accretive results
Whether trading on the NYSE, Nasdaq, Amex, TSX or TSX-V, our highly experienced research team will investigate prime investment opportunities on behalf of the MaybachFinancial.com subscribers to offer a comprehensive look at what is happening and why. Sign up today at www.maybachfinancial.com for a free 90-day subscription.
In addition to the analyst reviews, receive a complimentary subscription to the Maybach Service and receive at no cost our "Special Report #1: Protecting Our Future,""Special Report#2: Hearing is Believing," and a new report to be released shortly. No credit card or payment information is required.
Research reports are posted prior to market open to ensure investors get the latest information, as they need it. The reports vary by sector and markets by looking at various aspects of each company in an effort to provide an unbiased view and provide pertinent information so investors can make informed decisions regarding their portfolios.
Investors can gain access to this research by signing up at www.maybachfinancial.com for a complementary 90-day trial. Sign up today to avoid missing out.
Have a company you are following? Want more in-depth information? Become a subscriber to submit your request to us via email to info@maybachfinancial.com all members' requests will be completed. It's easy, just go to www.maybachfinancial.com and sign up then email us at info@maybachfinancial.com with the subject line (stock review).
Maybach Financial (Maybach) is not a registered broker dealer or a registered investment advisor. However, we do use information from licensed analysts. No information accessed through the Maybach Web site or this release constitutes a recommendation to buy, sell or hold any security in any jurisdiction. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. There is no financial relationship that exists between the issuer of this release and the company whose stock is mentioned in the release.
Analyst reviews may or may not contain all the information listed above as each opinion and review varies with each company reviewed.
Please view the disclaimer at http://www.maybachfinancial.com/terms.php Statements made in this release may include forward-looking statements and projections, made in reliance on the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Maybach has made every reasonable effort to ensure that the information and assumptions on which these statements and projections are based are current, reasonable, and complete. However, a variety of factors could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release. Maybach makes these statements and projections in good faith, neither Maybach nor its management can guarantee that the transactions will be consummated or that anticipated future results will be achieved. All material herein was based upon information believed to be reliable. The information contained herein is not guaranteed by Maybach to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Maybach assumes no obligation to publicly update or revise any forward-looking statements made herein or any other forward-looking statements made by Maybach, whether as a result of new information, future events, or otherwise.
CONTACT: Maybach Financial e-mail: info@maybachfinancial.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
|
|
